Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20330389 | 0.73 | PDCD1 (0.43) | PDCD1CD274HDAC2HDAC1TLR9 | |
| SCHEMBL107873 | 0.73 | PDCD1 (0.50) | PDCD1CD274HDAC2HDAC1TLR9 | |
| SCHEMBL2927941 | 0.73 | WDR5 (0.46) | — | |
| SCHEMBL15933517 | 0.73 | PDCD1 (0.43) | PDCD1CD274HDAC2HDAC1TLR9 | |
| SCHEMBL4072309 | 0.72 | HDAC2 (0.46) | PDCD1CD274HDAC2HDAC1TLR9 | |
| SCHEMBL870366 | 0.71 | ALDH1A1 (0.44) | HDAC2HDAC1 | |
| SCHEMBL15933428 | 0.71 | HDAC2 (0.51) | PDCD1CD274HDAC2HDAC1TLR9 | |
| SCHEMBL13531866 | 0.71 | HDAC2 (0.46) | PDCD1CD274HDAC2HDAC1TLR9 | |
| SCHEMBL15882090 | 0.70 | PDCD1 (0.45) | PDCD1CD274HDAC2HDAC1TLR9 | |
| SCHEMBL2928791 | 0.70 | ALDH1A1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
| EP-1583534-A4 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20060052382-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. | 2006-03-09 | — | — | US | disclosed |
| EP-1583534-A1 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004058266-A1 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052382-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | PDCD1 2968/4885CD274 4097/4885HDAC2 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.